{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:17:08Z","timestamp":1788369428746,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of\n                      <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 322) collected in the United States in 2020\u20132022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC\n                      <jats:sub>50\/90<\/jats:sub>\n                      values of 0.12 \u00b5g\/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00527-26","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:26:23Z","timestamp":1785763583000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    activity of zoliflodacin against\n                    <i>Neisseria gonorrhoeae<\/i>\n                    collected in the United States from 2020 to 2022"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7827-794X","authenticated-orcid":true,"given":"Sarah M.","family":"McLeod","sequence":"first","affiliation":[{"name":"Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc.","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-596X","authenticated-orcid":true,"given":"Samir H.","family":"Moussa","sequence":"additional","affiliation":[{"name":"Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc.","place":["Waltham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-2701","authenticated-orcid":true,"given":"Meredith","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA, Inc.","place":["Schaumburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Au","sequence":"additional","affiliation":[{"name":"Global Antibiotic R&D Partnership","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Daram","sequence":"additional","affiliation":[{"name":"Global Antibiotic R&D Partnership","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Centers for Disease Control and Prevention. 2022. Sexually transmitted infections surveillance. https:\/\/www.cdc.gov\/sti-statistics\/media\/pdfs\/2024\/11\/2022-STI-Surveillance-Report-PDF.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.15698\/mic2016.09.524"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf109"},{"key":"e_1_3_2_5_2","unstructured":"World Health Organization. 2025. Enhanced gonococcal antimicrobial surveillance programme (EGASP): gonorrhoea treatment optimization 2025 report. https:\/\/www.who.int\/publications\/i\/item\/9789240117297."},{"key":"e_1_3_2_6_2","unstructured":"CDC. 2019. 2019 antibiotic resistance threats report. Antimicrobial resistance. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00118-5"},{"key":"e_1_3_2_8_2","unstructured":"Entasis Therapeutics Inc. 2025. NUZOLVENCE\u00ae (zoliflodacin) for oral suspension. Prescribing information."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00021"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01953-1"},{"key":"e_1_3_2_11_2","unstructured":"US Centers for Disease Control and Prevention. Gonococcal isolate surveillance project (GISP). Available from: https:\/\/www.cdc.gov\/sti-statistics\/gisp-profiles\/index.html#:~:text=Findings%20from%20GISP%20directly%20contributed resistance%20have%20not%20been%20established. Accessed 22 June 2026"},{"key":"e_1_3_2_12_2","volume-title":"CLSI standard M07","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In CLSI standard M07, 11th ed. CLSI, Wayne, PA, USA.","edition":"11"},{"key":"e_1_3_2_13_2","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2026","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2026. Performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 36th ed. CLSI, Wayne, PA, USA.","edition":"36"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Food and Drug Administration. 2025. Antibacterial susceptibility test interpretive criteria. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/zoliflodacin-oral-products. Retrieved 22 Jun 2026."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021634"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04456-14"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.663534"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep11827"},{"key":"e_1_3_2_19_2","unstructured":"U.S. Centers for Disease Control and Prevention. 2026. CDC & FDA antimicrobial resistance isolate bank. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/php\/public-health-strategy\/index.html"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200899"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2025.100624"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae176"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00044-1"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.14826.1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab024"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00863-20"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0522"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad027"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00527-26","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00527-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:54:58Z","timestamp":1788368098000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00527-26"}},"subtitle":[],"editor":[{"given":"Boudewijn L.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1128\/aac.00527-26"],"URL":"https:\/\/doi.org\/10.1128\/aac.00527-26","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2026-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00527-26"}}